

Sten Myrehaug

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5155302/publications.pdf>

Version: 2024-02-01

76
papers

1,957
citations

257101

24
h-index

288905

40
g-index

80
all docs

80
docs citations

80
times ranked

2371
citing authors

#	ARTICLE	IF	CITATIONS
1	Stereotactic Ablative Radiotherapy for the Management of Liver Metastases from Neuroendocrine Neoplasms: A Preliminary Study. <i>Neuroendocrinology</i> , 2022, 112, 153-160.	1.2	10
2	Hypofractionated Stereotactic Radiation Therapy for Intact Brain Metastases in 5 Daily Fractions: Effect of Dose on Treatment Response. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 112, 342-350.	0.4	14
3	Predicting survival in patients with glioblastoma using MRI radiomic features extracted from radiation planning volumes. <i>Journal of Neuro-Oncology</i> , 2022, 156, 579-588.	1.4	5
4	Inter-fraction dynamics during post-operative 5 fraction cavity hypofractionated stereotactic radiotherapy with a MR LINAC: a prospective serial imaging study. <i>Journal of Neuro-Oncology</i> , 2022, 156, 569-577.	1.4	12
5	Spine Stereotactic Body Radiotherapy for Prostate Cancer Metastases and the Impact of Hormone Sensitivity Status on Local Control. <i>Neurosurgery</i> , 2022, 90, 743-749.	0.6	6
6	Pattern of Recurrence of Glioblastoma Versus Grade 4 IDH-Mutant Astrocytoma Following Chemoradiation: A Retrospective Matched-Cohort Analysis. <i>Technology in Cancer Research and Treatment</i> , 2022, 21, 153303382211096.	0.8	9
7	Quantitating Interfraction Target Dynamics During Concurrent Chemoradiation for Glioblastoma: A Prospective Serial Imaging Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 736-746.	0.4	36
8	Quantitative CEST and MT at 1.5T for monitoring treatment response in glioblastoma: early and late tumor progression during chemoradiation. <i>Journal of Neuro-Oncology</i> , 2021, 151, 267-278.	1.4	23
9	Local control and patterns of failure for α -Radioresistant β -spinal metastases following stereotactic body radiotherapy compared to a α -Radiosensitive β -reference. <i>Journal of Neuro-Oncology</i> , 2021, 152, 173-182.	1.4	24
10	Quantitative ^{68}Ga -DOTATATE PET/CT Parameters for the Prediction of Therapy Response in Patients with Progressive Metastatic Neuroendocrine Tumors Treated with ^{177}Lu -DOTATATE. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1406-1414.	2.8	40
11	Intravoxel incoherent motion (IVIM) modeling of diffusion MRI during chemoradiation predicts therapeutic response in IDH wildtype glioblastoma. <i>Radiotherapy and Oncology</i> , 2021, 156, 258-265.	0.3	18
12	Quantitative mapping of individual voxels in the peritumoral region of IDH-wildtype glioblastoma to distinguish between tumor infiltration and edema. <i>Journal of Neuro-Oncology</i> , 2021, 153, 251-261.	1.4	18
13	ADC, D, f dataset calculated through the simplified IVIM model, with MGMT promoter methylation, age, and ECOG, in 38 patients with wildtype IDH glioblastoma. <i>Data in Brief</i> , 2021, 35, 106950.	0.5	3
14	Magnetic Resonance Guided Radiation Therapy for Pancreatic Adenocarcinoma, Advantages, Challenges, Current Approaches, and Future Directions. <i>Frontiers in Oncology</i> , 2021, 11, 628155.	1.3	27
15	Risk of Cancer-Specific Death for Patients Diagnosed With Neuroendocrine Tumors: A Population-Based Analysis. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 935-944.	2.3	5
16	A pilot study of everolimus and radiation for neuroendocrine liver metastases. <i>Endocrine-Related Cancer</i> , 2021, 28, 541-548.	1.6	4
17	Outcomes of extra-cranial stereotactic body radiotherapy for metastatic breast cancer: Treatment indication matters. <i>Radiotherapy and Oncology</i> , 2021, 161, 159-165.	0.3	14
18	The Initial Step Towards Establishing a Quantitative, Magnetic Resonance Imaging-Based Framework for Response Assessment of Spinal Metastases After Stereotactic Body Radiation Therapy. <i>Neurosurgery</i> , 2021, 89, 884-891.	0.6	6

#	ARTICLE	IF	CITATIONS
19	Accuracy and precision of apparent diffusion coefficient measurements on a 1.5T MR-Linac in central nervous system tumour patients. <i>Radiotherapy and Oncology</i> , 2021, 164, 155-162.	0.3	19
20	Chemical exchange saturation transfer MRI in central nervous system tumours on a 1.5T MR-Linac. <i>Radiotherapy and Oncology</i> , 2021, 162, 140-149.	0.3	14
21	Incidence and Predictors of Second Primary Cancers in Patients With Neuroendocrine Tumors. <i>JAMA Oncology</i> , 2021, 7, 1718.	3.4	4
22	Prognostic Factors Associated With Surviving Less Than 3 Months vs Greater Than 3 Years Specific to Spine Stereotactic Body Radiotherapy and Late Adverse Events. <i>Neurosurgery</i> , 2021, 88, 971-979.	0.6	13
23	MR-guided focused ultrasound enhances delivery of trastuzumab to Her2-positive brain metastases. <i>Science Translational Medicine</i> , 2021, 13, eabj4011.	5.8	82
24	MRI radiomics to differentiate between low grade glioma and glioblastoma peritumoral region. <i>Journal of Neuro-Oncology</i> , 2021, 155, 181-191.	1.4	29
25	BRAF V600E mutant oligodendroglioma-like tumors with chromosomal instability in adolescents and young adults. <i>Brain Pathology</i> , 2020, 30, 515-523.	2.1	8
26	Outcomes of extra-cranial stereotactic body radiotherapy for metastatic colorectal cancer: Dose and site of metastases matter. <i>Radiotherapy and Oncology</i> , 2020, 142, 236-245.	0.3	27
27	Predictors of leptomeningeal disease following hypofractionated stereotactic radiotherapy for intact and resected brain metastases. <i>Neuro-Oncology</i> , 2020, 22, 84-93.	0.6	39
28	Material deprivation and access to cancer care in a universal health care system. <i>Cancer</i> , 2020, 126, 4545-4552.	2.0	12
29	Commonwealth Neuroendocrine Tumour Research Collaboration and the North American Neuroendocrine Tumor Society Guidelines for the Diagnosis and Management of Patients With Lung Neuroendocrine Tumors: An International Collaborative Endorsement and Update of the 2015 European Neuroendocrine Tumor Society Expert Consensus Guidelines. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1577-1598.	0.5	58
30	Glioma consensus contouring recommendations from a MR-Linac International Consortium Research Group and evaluation of a CT-MRI and MRI-only workflow. <i>Journal of Neuro-Oncology</i> , 2020, 149, 305-314.	1.4	25
31	Mature Imaging-Based Outcomes Supporting Local Control for Complex Reirradiation Salvage Spine Stereotactic Body Radiotherapy. <i>Neurosurgery</i> , 2020, 87, 816-822.	0.6	10
32	Dose-Escalated Radiation Therapy for Pancreatic Cancer: A Simultaneous Integrated Boost Approach. <i>Practical Radiation Oncology</i> , 2020, 10, e495-e507.	1.1	50
33	Adverse Radiation Effect After Hypofractionated Stereotactic Radiosurgery in 5 Daily Fractions for Surgical Cavities and Intact Brain Metastases. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 106, 772-779.	0.4	36
34	The benefits of upfront primary tumor resection for metastatic small bowel neuroendocrine tumors: A population-based analysis.. <i>Journal of Clinical Oncology</i> , 2020, 38, 620-620.	0.8	2
35	Risk of cancer-specific death for patients diagnosed with neuroendocrine tumors: A population-based analysis.. <i>Journal of Clinical Oncology</i> , 2020, 38, 4605-4605.	0.8	0
36	Proof of concept for stereotactic body radiation therapy in the treatment of functional neuroendocrine neoplasms. <i>Journal of Radiosurgery and SBRT</i> , 2020, 6, 321-324.	0.2	1

#	ARTICLE	IF	CITATIONS
37	Clinical Image Coregistration Variability on a Dedicated Radiosurgery Unit. <i>Neurosurgery</i> , 2019, 85, E101-E108.	0.6	5
38	Single-Fraction Stereotactic Radiosurgery Versus Hippocampal-Avoidance Whole Brain Radiation Therapy for Patients With 10 to 30 Brain Metastases: A Dosimetric Analysis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, 394-399.	0.4	23
39	Spinal metastasis: diagnosis, management and follow-up. <i>British Journal of Radiology</i> , 2019, 92, 20190211.	1.0	29
40	Quantification of pulsed saturation transfer at 1.5T and 3T. <i>Magnetic Resonance in Medicine</i> , 2019, 82, 1684-1699.	1.9	5
41	Improved dosimetric accuracy with semi-automatic contour propagation of organs-at-risk in glioblastoma patients undergoing chemoradiation. <i>Journal of Applied Clinical Medical Physics</i> , 2019, 20, 45-53.	0.8	7
42	Postoperative Stereotactic Body Radiotherapy for Spinal Metastases and the Impact of Epidural Disease Grade. <i>Neurosurgery</i> , 2019, 85, E1111-E1118.	0.6	26
43	Economic Analysis of Adjuvant Chemoradiotherapy Compared with Chemotherapy in Resected Pancreas Cancer. <i>Annals of Surgical Oncology</i> , 2019, 26, 4193-4203.	0.7	3
44	Low rates of specialized cancer consultation and cancer-directed therapy for noncurable pancreatic adenocarcinoma: a population-based analysis. <i>Cmaj</i> , 2019, 191, E574-E580.	0.9	21
45	Image-Guided, Linac-Based, Surgical Cavity-Hypofractionated Stereotactic Radiotherapy in 5 Daily Fractions for Brain Metastases. <i>Neurosurgery</i> , 2019, 85, E860-E869.	0.6	34
46	LGG-01. BRAF V600E MUTANT OLIGODENDROGLIOMA-LIKE TUMORS WITH CHROMOSOMAL INSTABILITY IN ADOLESCENT AND YOUNG ADULT. <i>Neuro-Oncology</i> , 2019, 21, ii98-ii98.	0.6	0
47	Stereotactic Body Radiotherapy (SBRT) for Oligometastatic Spine Metastases: An Overview. <i>Frontiers in Oncology</i> , 2019, 9, 337.	1.3	74
48	Patterns of Symptoms Burden in Neuroendocrine Tumors: A Population-Based Analysis of Prospective Patient-Reported Outcomes. <i>Oncologist</i> , 2019, 24, 1384-1394.	1.9	16
49	Quantitative MRI Biomarkers of Stereotactic Radiotherapy Outcome in Brain Metastasis. <i>Scientific Reports</i> , 2019, 9, 19830.	1.6	46
50	Stereotactic Body Radiotherapy for Spinal Metastases at the Extreme Ends of the Spine: Imaging-Based Outcomes for Cervical and Sacral Metastases. <i>Neurosurgery</i> , 2019, 85, 605-612.	0.6	20
51	Survival and cost associated with chemotherapy and chemoradiotherapy among resected pancreas cancer patients.. <i>Journal of Clinical Oncology</i> , 2019, 37, 351-351.	0.8	1
52	Symptom burden at the end of life for neuroendocrine tumors: A population-based analysis of patient-reported outcomes.. <i>Journal of Clinical Oncology</i> , 2019, 37, 297-297.	0.8	2
53	Quantitative Magnetization Transfer in Monitoring Glioblastoma (GBM) Response to Therapy. <i>Scientific Reports</i> , 2018, 8, 2475.	1.6	31
54	Vertebral Compression Fracture After Spine Stereotactic Body Radiation Therapy: A Review of the Pathophysiology and Risk Factors. <i>Neurosurgery</i> , 2018, 83, 314-322.	0.6	104

#	ARTICLE	IF	CITATIONS
55	Evaluation of Glioblastoma Response to Therapy With Chemical Exchange Saturation Transfer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 713-723.	0.4	58
56	Glioblastoma (GBM) effects on quantitative MRI of contralateral normal appearing white matter. <i>Journal of Neuro-Oncology</i> , 2018, 139, 97-106.	1.4	18
57	Imaging-Based Outcomes for 24ÂGy in 2 Daily Fractions for Patients with de Novo Spinal Metastases Treated With Spine Stereotactic Body Radiation Therapy (SBRT). <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 499-507.	0.4	83
58	Stereotactic radiosurgery for resected brain metastasis: Cavity dynamics and factors affecting its evolution. <i>Journal of Radiosurgery and SBRT</i> , 2018, 5, 191-200.	0.2	8
59	Positional Accuracy of Treating Multiple Versus Single Vertebral Metastases With Stereotactic Body Radiotherapy. <i>Technology in Cancer Research and Treatment</i> , 2017, 16, 231-237.	0.8	10
60	Spine Stereotactic Body Radiotherapy: Indications, Outcomes, and Points of Caution. <i>Global Spine Journal</i> , 2017, 7, 179-197.	1.2	79
61	Differentiating radiation necrosis from tumor progression in brain metastases treated with stereotactic radiotherapy: utility of intravoxel incoherent motion perfusion MRI and correlation with histopathology. <i>Journal of Neuro-Oncology</i> , 2017, 134, 433-441.	1.4	59
62	Reirradiation spine stereotactic body radiation therapy for spinal metastases: systematic review. <i>Journal of Neurosurgery: Spine</i> , 2017, 27, 428-435.	0.9	113
63	Spinal metastases: multimodality imaging in diagnosis and stereotactic body radiation therapy planning. <i>Future Oncology</i> , 2017, 13, 77-91.	1.1	17
64	Volume of Lytic Vertebral Body Metastatic Disease Quantified Using Computed Tomographyâ€‘Based Image Segmentation Predicts Fracture Risk After Spine Stereotactic Body Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 97, 75-81.	0.4	35
65	Investigation of irradiated volume in linac-based brain hypo-fractionated stereotactic radiotherapy. <i>Radiation Oncology</i> , 2017, 12, 117.	1.2	2
66	A randomized phase II/III study comparing stereotactic body radiotherapy (SBRT) versus conventional palliative radiotherapy (CRT) for patients with spinal metastases (NCT02512965).. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS10129-TPS10129.	0.8	10
67	Postoperative stereotactic body radiotherapy for spinal metastases. <i>Chinese Clinical Oncology</i> , 2017, 6, S18-S18.	0.4	12
68	Hospitalizations in elderly glioblastoma patients.. <i>Journal of Clinical Oncology</i> , 2017, 35, e21529-e21529.	0.8	0
69	A rapid inversion technique for the measurement of longitudinal relaxation times of brain metabolites: application to lactate in highâ€‘grade gliomas at 3 T. <i>NMR in Biomedicine</i> , 2016, 29, 1381-1390.	1.6	10
70	Why hypofractionate stereotactic radiosurgery for brain metastases?. <i>CNS Oncology</i> , 2016, 5, 111-113.	1.2	5
71	Stereotactic body radiotherapy for pancreatic cancer: recent progress and future directions. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 523-530.	1.1	28
72	The era of stereotactic body radiotherapy for spinal metastases and the multidisciplinary management of complex cases. <i>Neuro-Oncology Practice</i> , 2016, 3, 48-58.	1.0	16

#	ARTICLE	IF	CITATIONS
73	A Treatment Planning and Acute Toxicity Comparison of Two Pelvic Nodal Volume Delineation Techniques and Delivery Comparison of Intensity-Modulated Radiotherapy Versus Volumetric Modulated Arc Therapy for Hypofractionated High-Risk Prostate Cancer Radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 82, e657-e662.	0.4	32
74	A population-based study of cardiac morbidity among Hodgkin lymphoma patients with preexisting heart disease. <i>Blood</i> , 2010, 116, 2237-2240.	0.6	63
75	Rapidly progressive bone destruction of the finger as first presentation of systemic metastases from lung cancer. <i>BMJ Case Reports</i> , 2010, 2010, bcr0520091912-bcr0520091912.	0.2	4
76	Cardiac morbidity following modern treatment for Hodgkin lymphoma: Supra-additive cardiotoxicity of doxorubicin and radiation therapy. <i>Leukemia and Lymphoma</i> , 2008, 49, 1486-1493.	0.6	144